https://www.synconaltd.com/
2024-02-08T07:22:59+00:00
https://www.synconaltd.com/about-us/
2024-02-08T07:00:24+00:00
https://www.synconaltd.com/about-us/who-we-are/
2023-09-29T15:04:57+00:00
https://www.synconaltd.com/about-us/our-model/
2023-07-13T13:02:21+00:00
https://www.synconaltd.com/about-us/our-investment-process/
2023-06-28T06:25:56+00:00
https://www.synconaltd.com/about-us/our-purpose-culture-and-values/
2023-08-10T08:28:37+00:00
https://www.synconaltd.com/about-us/our-history/
2024-02-08T07:23:30+00:00
https://www.synconaltd.com/our-people/
2023-08-07T14:53:11+00:00
https://www.synconaltd.com/our-people/melanie-gee/
2023-06-12T13:46:45+00:00
https://www.synconaltd.com/our-people/chris-hollowood/
2024-02-08T07:31:44+00:00
https://www.synconaltd.com/our-people/roel-bulthuis/
2023-11-30T11:09:02+00:00
https://www.synconaltd.com/our-people/rolf-soderstrom/
2023-11-28T15:00:54+00:00
https://www.synconaltd.com/our-people/markus-john/
2023-07-13T12:25:57+00:00
https://www.synconaltd.com/our-people/edward-hodgkin/
2024-01-24T16:26:50+00:00
https://www.synconaltd.com/our-people/john-tsai/
2024-02-07T10:10:14+00:00
https://www.synconaltd.com/our-people/elisa-petris/
2023-09-27T08:23:42+00:00
https://www.synconaltd.com/our-people/magdalena-jonikas/
2023-09-27T08:23:38+00:00
https://www.synconaltd.com/our-people/alex-hamilton/
2023-09-27T08:23:54+00:00
https://www.synconaltd.com/our-people/michael-kyriakides/
2023-09-27T08:23:48+00:00
https://www.synconaltd.com/our-people/gonzalo-garcia/
2023-09-27T08:23:47+00:00
https://www.synconaltd.com/our-people/alice-renard/
2023-09-27T08:23:55+00:00
https://www.synconaltd.com/our-people/raghd-rostom/
2023-09-27T08:23:53+00:00
https://www.synconaltd.com/our-people/nathaniel-dahan/
2023-09-27T08:23:41+00:00
https://www.synconaltd.com/our-people/alasdair-moodie/
2023-11-28T15:51:54+00:00
https://www.synconaltd.com/our-people/kenneth-galbraith/
2023-12-05T12:23:38+00:00
https://www.synconaltd.com/our-people/lisa-bright/
2024-02-07T16:59:15+00:00
https://www.synconaltd.com/our-people/annabel-clark/
2024-02-08T13:32:32+00:00
https://www.synconaltd.com/our-people/andrew-cossar/
2023-12-05T12:23:31+00:00
https://www.synconaltd.com/our-people/sarah-crabtree/
2023-12-05T12:23:37+00:00
https://www.synconaltd.com/our-people/nisha-sethi/
2023-12-05T12:23:30+00:00
https://www.synconaltd.com/our-people/kate-butler/
2024-02-08T07:00:26+00:00
https://www.synconaltd.com/our-people/stephen-molumby/
2023-12-05T12:23:39+00:00
https://www.synconaltd.com/our-people/christina-seed/
2023-12-05T12:23:36+00:00
https://www.synconaltd.com/our-people/fiona-fernandez/
2024-02-20T11:56:03+00:00
https://www.synconaltd.com/our-people/caroline-horsford/
2024-02-20T15:37:49+00:00
https://www.synconaltd.com/our-people/gemma-mountford/
2024-02-20T16:46:45+00:00
https://www.synconaltd.com/our-people/virginia-holmes/
2023-12-05T12:23:25+00:00
https://www.synconaltd.com/our-people/rob-hutchinson/
2023-12-05T12:23:35+00:00
https://www.synconaltd.com/our-people/kemal-malik/
2023-12-05T12:23:37+00:00
https://www.synconaltd.com/our-people/gian-piero-reverberi/
2023-12-05T12:23:26+00:00
https://www.synconaltd.com/our-people/fergus-witt/
2023-12-05T12:23:24+00:00
https://www.synconaltd.com/our-people/board-of-directors/
2023-12-05T12:23:40+00:00
https://www.synconaltd.com/our-people/board-of-directors/melanie-gee/
2023-06-28T06:00:46+00:00
https://www.synconaltd.com/our-people/board-of-directors/virginia-holmes/
2023-06-28T06:00:46+00:00
https://www.synconaltd.com/our-people/board-of-directors/rob-hutchinson/
2023-09-27T08:23:56+00:00
https://www.synconaltd.com/our-people/board-of-directors/kemal-malik/
2023-06-12T13:47:12+00:00
https://www.synconaltd.com/our-people/board-of-directors/gian-piero-reverberi/
2023-06-12T13:47:12+00:00
https://www.synconaltd.com/our-people/board-of-directors/cristina-csimma/
2024-03-11T13:27:08+00:00
https://www.synconaltd.com/our-people/board-of-directors/julie-cherrington/
2023-06-28T06:00:47+00:00
https://www.synconaltd.com/our-people/gwenaelle-pemberton/
2023-12-05T12:23:40+00:00
https://www.synconaltd.com/our-people/kunjan-zaveri/
2024-02-09T10:03:23+00:00
https://www.synconaltd.com/our-people/ben-woolven/
2024-02-09T10:04:56+00:00
https://www.synconaltd.com/our-people/nikki-padden/
2024-02-09T10:04:07+00:00
https://www.synconaltd.com/our-people/william-dutson/
2023-12-05T12:23:38+00:00
https://www.synconaltd.com/our-people/usman-sherani/
2023-12-05T12:23:30+00:00
https://www.synconaltd.com/our-people/hitesh-thakrar/
2024-02-08T07:43:01+00:00
https://www.synconaltd.com/our-people/alessio-d-addabbo/
2024-03-12T11:05:30+00:00
https://www.synconaltd.com/portfolio/
2024-02-08T07:00:24+00:00
https://www.synconaltd.com/portfolio/portfolio-data/
2023-06-12T14:35:30+00:00
https://www.synconaltd.com/portfolio/late-stage-clinical-companies/
2024-02-08T07:24:43+00:00
https://www.synconaltd.com/portfolio/late-stage-clinical-companies/autolus-therapeutics/
2024-02-08T07:27:29+00:00
https://www.synconaltd.com/portfolio/late-stage-clinical-companies/autolus-therapeutics/dr-christian-itin/
2023-09-26T15:22:59+00:00
https://www.synconaltd.com/portfolio/late-stage-clinical-companies/autolus-therapeutics/dr-martin-pule/
2023-09-26T15:22:41+00:00
https://www.synconaltd.com/portfolio/late-stage-clinical-companies/beacon-therapeutics/
2024-02-08T07:29:07+00:00
https://www.synconaltd.com/portfolio/late-stage-clinical-companies/beacon-therapeutics/david-fellows/
2023-09-26T15:22:51+00:00
https://www.synconaltd.com/portfolio/clinical-companies/
2024-02-08T07:25:37+00:00
https://www.synconaltd.com/portfolio/clinical-companies/achilles-therapeutics/
2024-02-08T07:29:38+00:00
https://www.synconaltd.com/portfolio/clinical-companies/achilles-therapeutics/iraj-ali/
2023-09-26T15:22:41+00:00
https://www.synconaltd.com/portfolio/clinical-companies/achilles-therapeutics/karl-peggs/
2023-09-26T15:22:57+00:00
https://www.synconaltd.com/portfolio/clinical-companies/achilles-therapeutics/prof-charles-swanton/
2023-09-26T15:22:59+00:00
https://www.synconaltd.com/portfolio/clinical-companies/achilles-therapeutics/prof-mark-lowdell/
2023-09-26T15:22:39+00:00
https://www.synconaltd.com/portfolio/clinical-companies/achilles-therapeutics/prof-sergio-quezada/
2023-09-26T15:22:37+00:00
https://www.synconaltd.com/portfolio/clinical-companies/swanbio-therapeutics/
2024-02-08T07:29:56+00:00
https://www.synconaltd.com/portfolio/clinical-companies/swanbio-therapeutics/tom-anderson/
2023-09-26T15:22:50+00:00
https://www.synconaltd.com/portfolio/clinical-companies/swanbio-therapeutics/florian-eichler/
2023-09-26T15:22:42+00:00
https://www.synconaltd.com/portfolio/clinical-companies/swanbio-therapeutics/rachel-salzman/
2023-09-26T15:22:43+00:00
https://www.synconaltd.com/portfolio/clinical-companies/swanbio-therapeutics/karen-kozarsky/
2023-09-26T15:22:58+00:00
https://www.synconaltd.com/portfolio/clinical-companies/freeline-therapeutics/
2024-02-08T07:30:20+00:00
https://www.synconaltd.com/portfolio/clinical-companies/freeline-therapeutics/michael-parini/
2023-09-26T15:22:40+00:00
https://www.synconaltd.com/portfolio/clinical-companies/freeline-therapeutics/professor-amit-nathwani/
2023-09-26T15:22:51+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/
2024-02-08T07:00:27+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/iain-mcgill/
2023-09-26T15:22:47+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-giovanna-lombardi/
2023-09-26T15:22:46+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/dr-marc-martinez-llordella/
2023-09-26T15:22:48+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-alberto-sanchez-fueyo/
2023-09-26T15:22:53+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-hans-stauss/
2023-09-26T15:22:37+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-emma-morris/
2023-09-26T15:22:44+00:00
https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/dr-elmar-jaeckel/
2023-09-26T15:22:51+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/
2024-02-08T07:33:14+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/resolution-therapeutics/
2024-02-08T07:00:26+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/resolution-therapeutics/amir-hefni/
2023-09-26T15:23:00+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/resolution-therapeutics/prof-stuart-forbes/
2023-09-26T15:22:43+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/resolution-therapeutics/prof-john-campbell/
2023-09-26T15:22:42+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/anaveon/
2024-02-08T07:19:34+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/anaveon/andreas-katopodis/
2023-09-26T15:22:41+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/purespring-therapeutics/
2024-02-08T07:00:26+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/purespring-therapeutics/julian-hanak/
2023-09-26T15:22:44+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/purespring-therapeutics/moin-saleem/
2023-09-26T15:22:44+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/clade-therapeutics/
2024-02-08T07:00:26+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/clade-therapeutics/chad-cowan/
2023-09-26T15:22:40+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/clade-therapeutics/jim-glasheen/
2023-09-26T15:22:49+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/clade-therapeutics/leandro-vetcher/
2023-09-26T15:22:55+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/
2024-02-08T07:00:27+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/ros-deegan/
2023-09-26T15:22:58+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/professor-dame-carol-robinson/
2023-09-26T15:22:55+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/dr-jonathan-hopper/
2023-09-26T15:22:42+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/dr-idlir-liko/
2023-09-26T15:22:43+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/hsin-yung-yen/
2023-09-26T15:22:41+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/mosaic-therapeutics/
2024-02-08T07:00:27+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/mosaic-therapeutics/brian-gladsden/
2023-09-26T15:22:57+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/mosaic-therapeutics/adrian-ibrahim/
2023-09-26T15:22:54+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/mosaic-therapeutics/mathew-garnett/
2023-09-26T15:22:54+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/mosaic-therapeutics/emile-voest/
2023-09-26T15:22:38+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/kesmalea-therapeutics/
2024-02-08T07:00:27+00:00
https://www.synconaltd.com/portfolio/pre-clinical-companies/kesmalea-therapeutics/harry-finch/
2023-09-26T15:22:49+00:00
https://www.synconaltd.com/portfolio/syncona-investments/
2024-02-08T07:00:25+00:00
https://www.synconaltd.com/portfolio/syncona-investments/forcefield-therapeutics/
2024-01-08T19:18:22+00:00
https://www.synconaltd.com/portfolio/syncona-investments/forcefield-therapeutics/mauro-giacca/
2023-09-26T15:22:39+00:00
https://www.synconaltd.com/portfolio/syncona-investments/forcefield-therapeutics/john-tsai/
2023-09-27T08:41:14+00:00
https://www.synconaltd.com/portfolio/syncona-investments/forcefield-therapeutics/dan-gliddon/
2023-09-27T08:38:38+00:00
https://www.synconaltd.com/portfolio/previous-investments/
2024-01-09T10:10:05+00:00
https://www.synconaltd.com/portfolio/previous-investments/gyroscope-therapeutics/
2024-01-09T10:10:09+00:00
https://www.synconaltd.com/portfolio/previous-investments/blue-earth/
2024-01-09T10:10:06+00:00
https://www.synconaltd.com/portfolio/previous-investments/nightstar/
2024-01-09T10:10:09+00:00
https://www.synconaltd.com/portfolio/previous-investments/neogene-therapeutics/
2024-01-09T10:10:08+00:00
https://www.synconaltd.com/portfolio/previous-investments/14mg/
2024-01-09T10:10:06+00:00
https://www.synconaltd.com/portfolio/previous-investments/azeria-therapeutics/
2024-01-09T10:10:07+00:00
https://www.synconaltd.com/sustainability/
2023-09-20T10:42:50+00:00
https://www.synconaltd.com/sustainability/message-from-ceo-siml/
2023-06-15T13:49:09+00:00
https://www.synconaltd.com/sustainability/our-approach-to-sustainability-reporting/
2023-08-10T08:15:47+00:00
https://www.synconaltd.com/sustainability/our-social-impact/
2023-06-15T07:51:14+00:00
https://www.synconaltd.com/sustainability/responsible-investor-and-partner/
2023-06-15T07:54:13+00:00
https://www.synconaltd.com/sustainability/responsible-investor-and-partner/responsible-investment-process/
2023-06-15T07:20:25+00:00
https://www.synconaltd.com/sustainability/responsible-investor-and-partner/a-responsible-partner/
2023-06-15T15:53:13+00:00
https://www.synconaltd.com/sustainability/inspiring-and-empowering-our-people/
2023-09-06T09:08:22+00:00
https://www.synconaltd.com/sustainability/responsible-and-ethical-business/
2023-06-22T08:50:15+00:00
https://www.synconaltd.com/sustainability/responsible-and-ethical-business/environment/
2023-06-15T14:03:09+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/
2023-06-15T13:57:51+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/
2023-06-15T06:00:47+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/alzheimer-s-research-uk/
2023-07-11T15:55:41+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/alzheimer-s-society/
2023-07-11T16:07:32+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/auditory-verbal-uk/
2023-07-11T16:11:58+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/the-brain-tumour-charity/
2023-07-11T16:21:04+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/butterfly-thyroid-cancer-trust/
2023-07-13T08:52:53+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/child-bereavement-uk/
2023-07-13T09:02:38+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/cure-leukaemia/
2023-07-13T09:11:50+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/david-nott-foundation/
2023-07-17T08:32:06+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/downside-up/
2023-07-17T08:34:39+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/the-egmont-trust/
2023-07-17T14:24:24+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/fight-for-sight/
2023-07-17T14:26:25+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/generating-genius/
2023-07-17T15:02:32+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/the-institute-of-cancer-research/
2023-07-18T08:34:21+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/james-place/
2023-07-18T08:40:51+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/jdrf/
2023-07-18T10:17:54+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/great-ormond-street-hospital/
2023-07-18T10:21:20+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/the-macular-society/
2023-07-18T10:23:35+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/maggie-s/
2023-07-18T10:28:10+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/marie-curie/
2023-07-18T10:32:58+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/nspcc/
2023-07-18T10:41:05+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/the-royal-marsden-cancer-charity/
2023-07-18T13:32:08+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/supporting-wounded-veterans/
2023-07-18T13:32:09+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/ssafa-the-armed-forces-charity/
2023-07-18T13:53:58+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/place2be/
2023-07-18T13:32:09+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/the-listening-place/
2023-07-18T13:32:10+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/brainwaves/
2023-09-27T08:50:35+00:00
https://www.synconaltd.com/sustainability/syncona-s-approach-to-charity/the-syncona-foundation/the-ella-project/
2023-07-19T13:36:19+00:00
https://www.synconaltd.com/sustainability/sustainability-policies/
2023-06-20T13:29:53+00:00
https://www.synconaltd.com/news-and-insights/
2023-06-12T14:28:42+00:00
https://www.synconaltd.com/news-and-insights/news/
2023-06-12T14:28:42+00:00
https://www.synconaltd.com/news-and-insights/news/nightstarx-commences-first-phase-i-ii-gene-therapy-clinical-trial-for-patients-with-x-linked-retinitis-pigmentosa/
2024-01-08T18:17:08+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-receives-positive-chmp-opinion-for-axumin-fluciclovine-18f-for-pet-imaging-of-recurrent-prostate-cancer/
2024-01-08T18:17:08+00:00
https://www.synconaltd.com/news-and-insights/news/making-a-difference-for-patients-with-recurrent-prostate-cancer/
2024-01-08T18:17:08+00:00
https://www.synconaltd.com/news-and-insights/news/nightstarx-appoints-healthcare-finance-leader-senthil-sundaram-as-chief-financial-officerqqqqqqqqqqq/
2023-11-14T10:33:12+00:00
https://www.synconaltd.com/news-and-insights/news/advanced-accelerator-applications-and-blue-earth-diagnostics-announce-european-manufacturing-and-distribution-agreements-for-axumin-fluciclovine-18f-for-pet-imaging-of-recurrent-prostate-cancer/
2024-01-08T18:17:08+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-raises-45-million-to-fund-development-of-gene-therapies-for-blinding-retinal-diseases/
2021-06-02T16:23:50+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-therapeutics-appoints-anne-prener-as-chief-executive-officer/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-expanded-leadership-team/
2023-06-12T14:05:56+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-appoints-m2i-to-manufacture-and-distribute-axumin-in-ireland/
2021-07-16T12:42:42+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-appoints-dr-soraya-bekkali-as-chief-executive-officer/
2022-02-18T07:54:26+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-initial-results-from-falcon-trial-show-61-of-patients-with-suspected-recurrent-prostate-cancer-had-treatment-plan-changed-following-fluciclovine-18f-pet-ct-scan/
2021-06-02T16:24:18+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-and-ge-healthcare-sign-uk-manufacturing-agreement/
2021-06-02T16:10:24+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-and-seibersdorf-laboratories-announce-manufacturing-and-distribution-agreements-for-axumin-fluciclovine-18f-for-pet-imaging-of-recurrent-prostate-cancer/
2021-06-02T16:24:42+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-therapeutics-to-participate-in-multiple-conferences-in-november/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-publication-of-a-unique-therapeutic-approach-for-treatment-of-patients-with-t-cell-lymphomas-in-nature-medicine/
2021-06-02T16:23:26+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-presentation-of-data-for-car-t-cells-with-reduced-sensitivity-to-checkpoint-inhibition-at-the-2017-american-society-of-hematology-annual-meeting/
2021-07-16T13:01:32+00:00
https://www.synconaltd.com/news-and-insights/news/publication-of-pre-clinical-data-of-a-dual-targeting-car-for-treatment-of-multiple-myeloma/
2021-06-02T16:23:09+00:00
https://www.synconaltd.com/news-and-insights/news/cell-and-gene-therapy-catapult-announces-viral-vector-manufacturing-technology-collaboration-with-freeline-therapeutics/
2021-06-02T16:21:54+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-presentation-at-upcoming-asco-2018-genitourinary-cancers-symposium-on-fluciclovine-18f-pet-ct-impact-on-clinical-management-of-recurrent-prostate-cancer/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-addition-of-axumin-fluciclovine-f-18-to-nccn-guidelines-for-pet-imaging-for-suspected-recurrent-prostate-cancer/
2021-06-02T16:22:55+00:00
https://www.synconaltd.com/news-and-insights/news/former-chief-operating-officer-of-kite-pharma-cynthia-m-butitta-appointed-to-autolus-board-of-directors/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-publication-in-molecular-therapy-on-its-small-molecule-activated-fast-acting-permanent-off-switchqqqqqqqqqqqqqqqqq/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-oral-presentation-at-the-aacr-annual-meeting-of-a-phase-i-study-of-a-gd2-car-t-cell-therapy-in-patients-with-neuroblastoma/
2021-06-02T16:01:36+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-and-miltenyi-biotec-sign-strategic-supply-agreement/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-presentation-of-preliminary-data-showing-early-signs-of-clinical-activity-for-a-gd2-targeting-car-t-cell-therapy-in-a-solid-tumour-setting-at-the-aacr-annual-meeting/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-therapeutics-to-present-new-data-in-choroideremia-at-the-arvo-2018-annual-meeting/
2023-06-12T14:05:56+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-license-agreement-with-ucl-business-plc-for-clinical-stage-product-candidate-in-development-for-the-treatment-of-b-cell-malignancies/
2023-06-12T14:05:51+00:00
https://www.synconaltd.com/news-and-insights/news/results-from-blue-earth-diagnostics-locate-trial-show-59-of-patients-with-suspected-recurrent-prostate-cancer-had-change-in-management-plan-following-18f-fluciclovine-pet-ct-scan/
2021-05-11T13:48:56+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-appointment-of-linda-bain-to-its-board-of-directors/
2021-05-11T13:57:16+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-appointment-of-andrew-j-oakley-as-senior-vice-president-and-chief-financial-officer/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-expands-global-leadership-position-in-gene-therapy-with-foundation-of-new-companies/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-appoints-iason-sp-z-o-o-to-manufacture-and-distribute-axumin-fluciclovine-18f-in-poland/
2021-05-11T16:41:31+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-seeking-to-deliver-a-cure-for-choroideremia/
2023-06-12T14:05:54+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-shortlisted-for-prestigious-best-emerging-biotech-company-award/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-reports-q2-2018-financial-results/
2024-01-08T18:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-to-present-at-upcoming-investor-conferences/
2024-01-08T18:17:10+00:00
https://www.synconaltd.com/news-and-insights/news/the-journal-of-urology-publishes-results-from-blue-earth-diagnostics-locate-trial-of-role-of-18f-fluciclovine-pet-ct-imaging-in-the-management-of-men-with-recurrent-prostate-cancer/
2021-06-02T16:22:31+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-appoints-strategic-biotechnology-executive-paula-cobb-to-its-board-of-directors/
2024-01-08T18:17:10+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-announces-appointment-of-immuno-oncology-industry-leader-michael-f-giordano-m-d-to-its-board-of-directors/
2024-01-08T18:17:10+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-therapeutics-to-present-at-2018-cell-gene-meeting-on-the-mesa/
2021-06-02T16:19:34+00:00
https://www.synconaltd.com/news-and-insights/news/axumin-fluciclovine-18f-receives-positive-recommendation-from-transparency-committee-of-the-french-has-for-use-in-pet-imaging-of-suspected-recurrent-prostate-cancer/
2021-07-16T11:31:29+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-therapeutics-to-present-at-chardan-genetic-medicines-conference/
2021-06-02T16:19:48+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-wins-prestigious-best-emerging-biotech-award/
2021-06-02T16:20:04+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-fluciclovine-f-18-research-presentations-at-upcoming-astro-annual-meeting/
2021-06-02T16:19:07+00:00
https://www.synconaltd.com/news-and-insights/news/nightstar-therapeutics-to-participate-in-multiple-conferences-in-november-1/
2023-06-12T14:06:05+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-brian-m-silver-as-chief-financial-officer-and-head-of-corporate-development/
2024-01-08T18:17:10+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-led-consortium-secures-innovate-uk-funding-to-develop-a-suspension-platform-for-cost-effective-manufacture-of-novel-aav-gene-therapies/
2022-02-18T07:54:19+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-18f-fluciclovine-research-presentation-at-upcoming-society-for-neuro-oncology-sno-annual-scientific-meeting/
2021-06-02T16:18:17+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-results-of-investigational-phase-3-blinded-image-evaluation-study-of-18f-fluciclovine-pet-imaging-in-glioma/
2023-06-12T14:05:54+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-announces-14-million-series-a-financing-to-build-a-pipeline-of-proprietary-medicines/
2021-06-03T11:22:53+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-expands-its-senior-leadership-team/
2024-01-08T18:17:10+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-dr-edwin-moses-as-chairman-of-its-board-of-directors-and-dr-iraj-ali-as-chief-executive-officer/
2024-01-08T18:17:10+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-u-s-food-and-drug-administration-fda-filing-acceptance-of-supplemental-new-drug-application-snda-for-18f-fluciclovine-pet-imaging-in-glioma/
2021-06-02T16:17:03+00:00
https://www.synconaltd.com/news-and-insights/news/first-production-and-administration-of-axumin-fluciclovine-18f-in-france/
2021-06-02T16:16:46+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-enters-lease-with-alexandria-real-estate-equities-inc-for-future-commercial-scale-manufacturing-site-and-u-s-headquarters/
2021-07-16T11:15:37+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-receives-cta-approval-for-phase-i-ii-study-in-non-small-cell-lung-cancer/
2021-06-02T16:15:56+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-new-program-for-gaucher-disease-and-poster-presentations-at-the-15th-annual-world-symposium-2019-in-orlando-usa/
2021-06-02T16:15:37+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-axumin-fluciclovine-f-18-locate-study-presentation-at-upcoming-asco-2019-genitourinary-cancers-symposium-on-impact-on-clinical-management-of-recurrent-prostate-cancer/
2023-06-12T14:06:02+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-dr-markus-dangl-as-chief-scientific-officer/
2024-01-08T18:17:10+00:00
https://www.synconaltd.com/news-and-insights/news/first-production-and-administration-of-axumin-fluciclovine-18f-in-italy/
2021-07-16T11:21:41+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-receives-cta-approval-for-phase-i-ii-study-in-metastatic-or-recurrent-melanoma/
2021-06-02T16:15:10+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-i-ii-study-in-dry-amd/
2022-02-18T07:54:13+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-leads-chf-35-million-series-a-financing-in-anaveon-a-new-immuno-oncology-company/
2021-06-02T10:37:23+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-new-data-on-auto1-at-the-american-association-of-cancer-research-aacr-annual-meeting-2019/
2021-07-16T11:22:59+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-celebrates-five-year-anniversary/
2024-01-08T18:17:11+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-addition-of-axumin-fluciclovine-18f-to-eau-guidelines-for-imaging-in-patients-with-biochemical-recurrence-in-prostate-cancer/
2021-07-16T11:32:36+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-receives-fda-orphan-drug-designation-for-auto3-for-treatment-of-acute-lymphoblastic-leukemia/
2021-06-02T16:14:02+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-presentations-on-axumin-fluciclovine-f-18-18f-fluciclovine-and-18f-rhpsma-at-upcoming-american-urological-association-s-2019-annual-meeting/
2021-06-02T16:04:32+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-updates-on-the-company-s-aav-manufacturing-platform-at-the-american-society-of-gene-cell-therapy-asgct-22nd-annual-meeting/
2021-06-02T16:07:06+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-the-implementation-of-the-pall-corporation-icellis-bioreactor-system-to-enable-commercial-scale-in-house-manufacturing-of-aav-gene-therapies/
2021-06-02T16:13:34+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-secures-long-term-commercial-manufacturing-capacity-at-brammer-bio-for-haemophilia-b-gene-therapy/
2024-01-08T18:17:11+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-results-from-initial-clinical-experience-of-18f-rhpsma-7-pet-imaging-by-technical-university-of-munich/
2021-06-02T16:04:07+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-results-of-additional-analyses-from-locate-trial-evaluating-change-in-recurrent-prostate-cancer-management-following-axumin-imaging/
2021-06-02T16:04:15+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-appoints-rosamond-deegan-as-chief-executive-officer/
2021-07-16T12:59:12+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-continues-to-expand-access-to-axumin-in-europe/
2021-06-02T16:03:59+00:00
https://www.synconaltd.com/news-and-insights/news/consortium-led-by-freeline-with-partners-symbiosis-and-the-cell-and-gene-therapy-catapult-secure-funding-from-innovate-uk/
2021-07-16T11:10:58+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-data-highlighting-platform-technology-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021/
2021-06-02T15:07:48+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021/
2023-06-12T14:06:01+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-first-quarter-2021-financial-results-on-may-6/
2021-06-04T16:26:19+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-preclinical-data-and-phase-1-2-study-design-of-the-flt190-aav-gene-therapy-for-fabry-disease-at-the-6th-update-on-fabry-disease-in-prague/
2022-11-29T11:20:00+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-participate-in-upcoming-investor-conferences-in-june/
2021-06-02T16:06:51+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-participate-in-upcoming-investor-conferences-in-april-and-may-2021/
2023-06-12T14:06:02+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-receives-innovation-passport-and-entry-into-ilap-for-auto4-for-the-treatment-of-t-cell-receptor-constant-region-beta-chain-1-trbc1-positive-t-cell-lymphomas/
2021-06-02T15:08:43+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-appoints-lisa-bright-to-its-board-of-directors/
2021-06-02T10:43:50+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-appoints-jonathan-montagu-as-non-executive-director/
2024-01-08T18:17:11+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-highlights-presentations-on-axumin-fluciclovine-f-18-18f-fluciclovine-and-18f-rhpsma-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/
2023-06-12T14:06:03+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-senior-leadership-transition-and-completion-of-series-b-financing-milestones/
2021-07-16T12:58:34+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-founded-by-syncona-ltd-appoints-chief-executive/
2024-01-08T18:17:11+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-results-from-investigational-clinical-study-of-safety-and-effectiveness-of-18f-fluciclovine-pet-imaging-in-adult-glioma/
2021-06-02T16:04:50+00:00
https://www.synconaltd.com/news-and-insights/news/blue-earth-diagnostics-announces-highlights-of-technical-university-of-munich-presentations-on-initial-clinical-experience-with-18f-rhpsma-7-pet-imaging-in-high-risk-primary-and-biochemical-recurrent-prostate-cancer/
2021-06-02T16:06:13+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-preclinical-liver-directed-aav-gene-therapy-data-at-the-european-working-group-on-gaucher-disease-ewggd/
2021-06-02T16:03:37+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-publication-in-nature-medicine-of-data-supporting-the-development-of-auto1-for-treatment-of-patients-with-all/
2022-11-29T11:19:50+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-updated-data-for-first-cohort-of-two-patients-in-haemophilia-b-study/
2022-11-29T11:19:39+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-doses-patient-in-first-fabry-disease-aav-gene-therapy-trial-globally/
2021-06-02T16:02:51+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-named-a-fierce-15-company-by-fiercebiotech/
2021-06-02T16:03:03+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-changes-to-executive-leadership-team/
2021-07-16T12:58:02+00:00
https://www.synconaltd.com/news-and-insights/news/found-build-and-fund/
2024-01-08T18:17:11+00:00
https://www.synconaltd.com/news-and-insights/news/founding-quell-therapeutics/
2024-01-08T18:17:11+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-and-an-emerging-area-of-cell-therapy/
2021-06-02T16:02:06+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-beverley-carr-as-chief-business-officer/
2024-01-08T18:17:11+00:00
https://www.synconaltd.com/news-and-insights/news/an-introduction-to-gene-therapy/
2021-06-02T16:01:17+00:00
https://www.synconaltd.com/news-and-insights/news/building-syncona-s-gene-therapy-platform/
2021-06-02T16:01:11+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-jeffrey-chodakewitz-m-d-to-its-board-of-directors/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-receives-fda-orphan-drug-designation-for-auto1-for-treatment-of-acute-lymphoblastic-leukemia/
2021-07-16T11:24:05+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-preclinical-data-on-aut06ng-at-the-sitc-annual-meeting/
2023-06-12T14:06:00+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-appoints-kenneth-galbraith-as-executive-in-residence/
2021-06-02T10:38:49+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-receives-prime-designation-for-auto1-for-the-treatment-of-adult-all/
2021-06-02T15:09:02+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-at-upcoming-investor-conferences-april/
2021-06-02T10:37:43+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-announces-pricing-of-initial-public-offering/
2021-06-04T16:21:16+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-updated-manufacturing-facility-strategy-leveraging-its-uk-operations/
2021-06-02T15:09:33+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-receives-cta-approval-to-start-a-phase-i-ii-study-to-evaluate-the-safety-dosing-and-clinical-activity-of-anv419-in-patients-with-solid-tumors/
2021-06-02T15:09:51+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-appoints-marita-james-cpa-as-chief-financial-officer/
2023-06-12T14:06:05+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-colin-love-phd-to-board-of-directors/
2021-06-01T15:39:49+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-at-upcoming-investor-conferences/
2021-06-02T15:14:18+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-appoints-jessica-stitt-as-chief-financial-officer/
2023-06-12T14:05:59+00:00
https://www.synconaltd.com/news-and-insights/news/the-syncona-foundation-announces-301-500-donation-to-generating-genius/
2021-06-01T15:50:54+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference/
2021-06-02T15:14:54+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-expansion-of-executive-leadership/
2021-06-02T10:34:01+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-proposed-public-offering-in-the-united-states/
2021-06-03T11:24:54+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-data-on-its-gaucher-disease-and-fabry-disease-aav-based-gene-therapies-at-the-17th-annual-worldsymposium/
2022-11-29T11:19:32+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-and-host-conference-call-on-march-4/
2021-06-02T10:43:30+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-announces-ton-schumacher-ph-d-company-co-founder-awarded-2021-jeantet-collen-prize-for-translational-medicine/
2021-06-02T10:34:59+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-data-at-the-2021-virtual-congress-of-the-european-association-for-haemophilia-and-allied-disorders-eahad-and-the-17th-annual-worldsymposium-2021/
2021-06-02T15:15:38+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-appoints-alison-lawton-to-board-of-directors/
2021-06-02T10:34:17+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-arjan-roozen-as-vp-site-head-and-general-manager/
2021-06-02T10:39:36+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-appoints-new-chief-executive-officer/
2023-06-12T14:05:56+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-provides-business-outlook-for-2021-2022/
2021-06-02T15:16:28+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-participate-at-conferences-during-january-2021/
2021-06-02T15:16:12+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-participate-in-investor-conferences-through-january-2021/
2021-06-02T15:17:09+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/
2022-02-18T07:53:52+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-preclinical-data-on-aut06ng-at-the-sitc-annual-meeting/
2021-06-02T16:12:32+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-and-noile-immune-announce-licensing-agreement/
2021-06-02T16:00:39+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-lee-m-stern-as-vp-ir-external-communications/
2021-06-02T10:39:13+00:00
https://www.synconaltd.com/news-and-insights/news/professor-amit-nathwani-will-present-the-ham-wasserman-lecture-at-the-61st-ash-annual-meeting/
2021-06-02T16:00:16+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-julia-p-gregory-to-its-board-of-directors/
2021-07-16T12:57:13+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/
2021-06-02T15:59:43+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-appointments-of-industry-veterans-in-gene-therapy-ophthalmology-and-biopharmaceuticals-to-its-board-of-directors/
2022-02-18T07:53:45+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/
2021-07-16T11:35:03+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-announces-a-26-6m-series-a-financing-from-syncona-ltd/
2021-06-03T11:23:16+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-provide-outlook-for-2020-at-the-38th-annual-j-p-morgan-conference/
2021-06-02T15:58:04+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-chief-scientific-officer-dr-martin-pule-to-give-keynote-lecture-at-the-eha-ebmt-2nd-european-car-t-cell-meeting/
2021-06-02T15:59:28+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-robert-coutts-as-chief-financial-officer/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-closing-of-public-offering/
2021-06-03T11:25:01+00:00
https://www.synconaltd.com/news-and-insights/news/lorenz-mayr-appointed-as-entrepreneur-in-residence/
2021-07-16T12:56:46+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-of-new-auto6-phase-1-data-in-childhood-neuroblastoma-in-science-translational-medicine/
2023-06-12T14:06:04+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-expands-board-of-directors-with-appointments-of-proven-industry-leaders/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-theresa-heggie-as-chief-executive/
2023-06-12T14:06:05+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-founds-purespring-with-a-45m-series-a-financing/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-data-on-aav-based-gene-therapies-for-fabry-disease-and-gaucher-disease-at-the-16th-annual-worldsymposium-2020/
2021-06-02T15:59:16+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-strengthens-leadership-team-ahead-of-next-stage-of-company-growth/
2022-02-18T07:53:38+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-announces-27-5-million-extended-series-a-financing/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-at-the-3rd-annual-evercore-isi-health-conx-conference/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results-and-host-conference-call-on-march-3/
2021-05-12T15:39:56+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference/
2021-06-02T15:23:33+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-ii-horizon-trial-evaluating-investigational-gene-therapy-gt005-in-people-with-dry-age-related-macular-degeneration/
2022-02-18T07:53:31+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-announces-grant-of-european-patent-covering-use-of-selectively-expanded-t-cells-targeting-clonal-neoantigens-for-the-treatment-of-cancer/
2021-06-02T15:24:22+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-presentation-at-the-2020-society-for-immunotherapy-of-cancer-sitc-annual-meeting/
2021-06-02T15:26:22+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-third-quarter-2020-financial-results-and-operational-progress/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/omass-announces-acquisition-of-pharmacology-capabilities-from-excellerate-biosciences/
2021-07-16T12:54:00+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-at-the-cowen-40th-annual-health-care-conference/
2023-06-12T14:05:55+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-receives-orphan-drug-designation-from-the-european-commission-for-flt190-for-the-treatment-of-fabry-disease/
2021-06-02T15:58:47+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-professor-sergio-quezada-as-chief-scientific-officer/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-julie-krop-m-d-as-chief-medical-officer/
2024-01-08T18:17:12+00:00
https://www.synconaltd.com/news-and-insights/news/covid-19-syncona-business-update/
2024-01-08T18:17:13+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-mark-baldry-as-chief-commercial-officer/
2024-01-08T18:17:13+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-carsten-boess-to-the-board-of-directors/
2024-01-08T18:17:13+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-half-year-2020-financial-results-and-recent-business-highlights/
2024-01-08T18:17:13+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-enters-a-collaborative-research-agreement-with-the-hannover-medical-school/
2021-06-02T15:57:21+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-a-manufacturing-update-at-the-virtual-2020-aacr-annual-meeting/
2021-06-02T15:54:20+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-new-data-at-the-12th-annual-protein-and-antibody-engineering-summit/
2021-06-01T15:58:31+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-announces-series-a-expansion-to-fund-its-lead-program-and-grow-pipeline-in-gene-therapy-for-neurological-diseases/
2024-01-08T18:17:13+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-first-patient-received-investigational-gene-therapy-gt005-via-orbit-subretinal-delivery-system-in-ongoing-phase-i-ii-focus-trial/
2022-02-18T07:53:24+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-data-on-its-aav-gene-therapy-platform-and-programmes-at-the-23rd-annual-american-society-of-gene-cell-therapy-2020/
2021-06-02T15:57:10+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-enters-a-collaborative-research-agreement-with-the-university-of-sheffield/
2021-06-02T15:25:35+00:00
https://www.synconaltd.com/news-and-insights/news/danny-bar-zohar-joins-syncona-as-partner/
2021-06-16T11:46:47+00:00
https://www.synconaltd.com/news-and-insights/news/twist-bioscience-and-neogene-announce-broad-strategic-partnership-for-next-generation-personalized-t-cell-therapies/
2021-06-02T15:25:51+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-first-quarter-2020-financial-results-and-host-conference-call-on-may-7/
2024-01-08T18:17:13+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-professor-karl-peggs-as-chief-medical-officer/
2024-01-08T18:17:13+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-receives-orphan-drug-designation-from-the-fda-for-flt190-for-the-treatment-of-fabry-disease/
2021-06-02T15:56:59+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-appoints-former-roche-chairman-and-chief-executive-officer-franz-b-humer-ph-d-as-executive-chairman-of-board-of-directors/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-first-quarter-2020-financial-results-and-operational-progress/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-announces-formation-of-scientific-advisory-board/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-promotion-of-romuald-corbau-ph-d-to-chief-scientific-officer/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-supply-agreement-for-haemophilia-b-program/
2021-06-02T15:26:08+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-new-data-on-auto3-during-the-asco20-virtual-scientific-program/
2022-11-29T11:18:53+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-gt005-an-investigational-gene-therapy-for-dry-age-related-macular-degeneration/
2022-02-18T07:53:17+00:00
https://www.synconaltd.com/news-and-insights/news/omass-announces-publication-in-nature-methods/
2021-06-02T15:55:27+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-new-data-on-auto1-and-auto3-at-the-2020-eha-annual-meeting/
2022-11-29T11:18:59+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-new-data-at-the-virtual-2020-aacr-annual-meeting/
2021-06-02T15:29:38+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-raises-110-million-series-a-financing-to-develop-next-generation-fully-personalized-neo-antigen-t-cell-receptor-tcr-therapies/
2021-06-01T15:37:38+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-notice-of-annual-general-meeting-agm-on-thursday-june-18-2020/
2021-06-02T15:55:13+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-appointment-of-sean-bohen-to-the-board-of-directors/
2022-02-18T07:53:10+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-host-investor-conference-calls-through-june/
2021-06-02T15:54:59+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-participate-in-the-morgan-stanley-virtual-18th-annual-global-healthcare-conference/
2021-06-02T15:28:39+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto3-data-presented-at-esmo-and-to-participate-in-banking-conferences-through-september/
2021-06-02T15:27:51+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-doses-first-patient-in-phase-i-ii-study-in-recurrent-or-metastatic-malignant-melanoma-with-first-til-therapy-to-specifically-target-clonal-neoantigens/
2021-06-02T15:54:40+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-fda-clearance-for-orbit-subretinal-delivery-system/
2022-02-18T07:09:47+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-additional-data-on-auto3-in-dlbcl-during-the-asco20-virtual-scientific-program/
2022-11-29T11:18:40+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-initiation-of-phase-ii-programme-evaluating-its-investigational-gene-therapy-gt005-for-dry-age-related-macular-degeneration/
2022-02-18T07:09:31+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-appoints-steven-zelenkofske-do-as-chief-medical-officer/
2021-07-16T12:49:21+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-announces-appointment-of-leaders-in-retinal-disease-gene-therapy-and-the-complement-system-to-its-clinical-and-scientific-advisory-boards/
2022-02-18T07:09:23+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-changes-to-its-board-and-management-team/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reschedules-its-investor-eha-conference-call/
2021-06-02T15:29:07+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-second-quarter-2020-financial-results-and-host-conference-call-on-august-6/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-strengthens-its-board-with-the-appointments-of-dr-dhaval-patel-and-sir-robert-lechler-and-hires-dr-natalie-belmonte-as-svp-research-translation/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-appoints-dr-nathalie-franchimont-as-non-executive-director/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-auto1-and-auto3-data-at-the-2020-eha25-virtual-congress/
2022-11-29T11:18:33+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-new-preclinical-data-during-the-virtual-2020-aacr-annual-meeting/
2021-06-02T15:56:28+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/
2023-06-12T14:06:01+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-doses-first-patient-in-phase-i-ii-study-in-advanced-non-small-cell-lung-cancer/
2021-06-02T15:55:41+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-acceptance-of-late-breaking-abstract-at-the-international-society-on-thrombosis-and-haemostasis-isth-2020-meeting/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-additional-financing-plans/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-closes-120-million-series-c-financing-round/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-new-haemophilia-b-data-at-the-international-society-on-thrombosis-and-haemostasis-isth-2020-meeting/
2022-11-29T11:18:23+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-daniel-hood-as-chief-legal-officer/
2024-01-08T18:17:14+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-participate-at-the-2021-rbc-capital-markets-global-healthcare-conference/
2021-06-02T11:38:46+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-appoints-scott-mcmillan-ph-d-as-chief-technical-officer/
2024-01-08T18:17:15+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-raises-52-7-million-in-an-oversubscribed-series-c-financing-to-further-advance-the-development-of-personalised-t-cell-therapies-to-treat-solid-tumours/
2021-06-02T10:35:58+00:00
https://www.synconaltd.com/news-and-insights/news/nightstarx-appoints-ophthalmology-industry-veteran-scott-whitcup-to-board-of-directors/
2024-01-08T18:17:15+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-an-additional-nature-publication-for-auto1/
2023-06-12T14:05:59+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-appoints-brent-pfeiffenberger-pharm-d-mba-as-chief-operating-officer/
2021-06-07T16:36:04+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-innovation-licensing-and-access-pathway-ilap-designation-for-obe-cel-for-the-treatment-of-relapsed-refractory-adult-b-cell-all/
2021-06-15T12:03:15+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-doses-second-patient-of-phase-1-2-marvel-1-clinical-trial-for-fabry-disease/
2021-06-16T12:14:43+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-final-results-for-the-year-ended-31-march-2021/
2021-07-08T09:21:37+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-research-collaboration-agreement-with-children-s-medical-research-institute-to-develop-novel-gene-therapy-capsids/
2022-02-18T07:09:11+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-doses-first-patient-in-a-phase-i-ii-study-to-evaluate-the-safety-dosing-and-clinical-activity-of-anv419-in-patients-with-solid-tumors/
2021-07-08T09:20:29+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-announces-first-patient-enrolled-in-natural-history-study-to-evaluate-patients-with-adrenomyeloneuropathy/
2021-07-08T09:20:18+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-executive-leadership-changes/
2021-07-08T09:19:57+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-second-quarter-2021-financial-results-on-august-5-2021/
2021-07-08T12:05:12+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-appointment-of-edgar-braendle-m-d-ph-d-as-chief-development-officer/
2021-07-15T12:02:35+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-appoints-dominik-hartl-m-d-as-chief-medical-officer/
2024-01-08T18:17:15+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-and-moderna-sign-option-and-license-agreement-for-access-to-proprietary-targeting-technology-from-autolus/
2021-08-02T12:02:32+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-second-quarter-2021-financial-results-and-operational-progress/
2021-08-05T12:05:35+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-promising-innovative-medicine-pim-designation-for-obe-cel-for-the-treatment-of-relapsed-refractory-adult-b-cell-all/
2021-08-09T12:05:30+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-second-quarter-2021-financial-results-and-recent-business-highlights/
2021-08-10T12:05:59+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-provides-executive-leadership-team-update-company-to-provide-corporate-update-and-second-quarter-2021-financial-results-on-monday-august-16/
2021-08-13T11:35:24+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-michael-j-parini-as-chief-executive-officer-and-reports-second-quarter-2021-financial-results/
2021-10-19T10:25:02+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-announces-first-quarter-update/
2023-06-12T14:05:54+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-of-obe-cel-auto1-phase-1-allcar19-data-in-adults-with-relapsed-refractory-b-all-in-journal-of-clinical-oncology/
2022-11-29T11:18:15+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-strengthens-senior-leadership-with-appointment-of-chief-medical-officer-and-chief-development-officer/
2023-06-12T14:05:51+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-participate-in-upcoming-investor-conferences-in-september-2021/
2021-09-07T12:05:34+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-orphan-drug-designations-for-flt201-for-the-treatment-of-gaucher-disease/
2021-09-16T12:12:28+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-appoints-han-lee-ph-d-mba-as-chief-financial-officer/
2021-09-16T12:12:11+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-the-appointment-of-john-h-johnson-as-non-executive-chairman-of-its-board-of-directors/
2021-09-15T12:01:05+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk/
2021-09-16T12:11:54+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-significantly-expands-clinical-manufacturing-capacity-for-its-engineered-treg-cell-therapies-through-a-collaboration-with-the-cell-and-gene-therapy-catapult/
2021-09-24T11:07:40+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-announces-new-preclinical-data-demonstrating-proof-of-principle-for-sbt101-gene-therapy-as-a-potential-treatment-of-adrenomyeloneuropathy/
2021-10-19T11:26:24+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-presents-data-at-the-2021-european-society-for-gene-and-cell-therapy/
2022-11-29T11:18:01+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-granted-cta-approval-to-begin-first-clinical-trial-with-a-multi-modular-engineered-treg-cell-therapy/
2021-10-27T13:51:30+00:00
https://www.synconaltd.com/news-and-insights/news/clade-therapeutics-raises-87-million-series-a-financing-to-realise-the-potential-of-cell-therapy/
2021-11-03T11:24:18+00:00
https://www.synconaltd.com/news-and-insights/news/cambridge-epigenetix-raises-88-million-series-d-financing-to-advance-best-in-class-dna-sequencing-technology-platform/
2021-11-02T12:49:09+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-third-quarter-2021-financial-results-and-operational-progress/
2021-11-03T11:05:57+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-new-data-at-the-63rd-ash-annual-meeting-exposition/
2021-11-04T13:53:59+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
2021-11-04T08:34:45+00:00
https://www.synconaltd.com/news-and-insights/news/omass-unveils-rich-drug-discovery-pipeline-targeting-intractable-or-inadequately-drugged-membrane-and-complex-bound-proteins/
2021-11-04T08:39:20+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-therapeutics-to-present-flt180a-data-at-the-2021-ash-annual-meeting/
2021-11-04T13:11:29+00:00
https://www.synconaltd.com/news-and-insights/news/blackstone-life-sciences-to-invest-up-to-250-million-in-autolus-therapeutics-to-develop-obe-cel-in-adult-acute-lymphoblastic-leukemia-all-and-advance-broader-platform/
2021-11-08T07:00:11+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-sanofi-investment-of-up-to-60-million/
2022-02-18T07:08:21+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-third-quarter-2021-financial-results-and-recent-business-highlights/
2021-12-01T16:40:21+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-new-data-from-fabry-disease-program-pipeline-and-company-updates-including-appointment-of-pamela-foulds-md-as-chief-medical-officer-and-third-quarter-2021-financial-results/
2022-11-29T11:17:37+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-describing-its-small-molecule-regulated-car-t-cells/
2021-11-10T13:08:47+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-interim-results-for-the-six-months-ended-30-september-2021/
2021-11-11T07:02:40+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-poster-presentation-at-the-2021-society-for-immunotherapy-of-cancer-annual-meeting/
2021-11-12T12:05:11+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-presents-data-at-the-sitc-annual-meeting/
2022-11-29T11:17:21+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-the-appointment-of-dr-william-d-young-as-a-non-executive-director/
2021-11-15T12:03:34+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-raises-156-million-in-oversubscribed-series-b-financing-to-advance-its-pioneering-multi-modular-engineered-t-regulatory-treg-cell-therapy-pipeline-and-platform/
2021-11-29T07:06:17+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announce-new-time-for-investor-call-to-discuss-data-presented-at-the-63rd-ash-annual-meeting-exposition/
2021-12-06T13:33:08+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-announces-appointment-of-tony-adamis-to-board-of-directors/
2022-02-18T07:08:08+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-presents-positive-data-at-esmo-i-o-congress-2021-on-high-dose-manufacturing-process-for-precision-t-cell-therapies-targeting-clonal-neoantigens/
2022-11-29T11:17:04+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-positive-obe-cel-data-at-the-63rd-ash-annual-meeting-exposition/
2022-11-29T11:16:23+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-long-term-follow-up-data-from-phase-1-2-b-amaze-trial-in-hemophilia-b-at-the-2021-ash-annual-meeting/
2022-11-29T11:16:41+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-2022-corporate-priorities-and-guidance/
2021-12-23T09:28:42+00:00
https://www.synconaltd.com/news-and-insights/news/omass-founder-professor-dame-carol-robinson-honoured-with-the-2022-louis-jeantet-prize-for-medicine-and-the-2022-benjamin-franklin-medal-in-chemistry/
2023-06-12T14:05:50+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-to-raise-chf-110-million-in-oversubscribed-series-b-financing/
2021-12-16T12:53:03+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-appoints-raphael-rousseau-m-d-ph-d-as-chief-medical-officer/
2023-06-12T14:05:52+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-added-to-the-nasdaq-biotechnology-index/
2021-12-20T14:19:18+00:00
https://www.synconaltd.com/news-and-insights/news/gyroscope-therapeutics-to-be-acquired-for-up-to-1-5-billion/
2022-02-18T07:07:50+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-participate-in-conferences-during-january-2022/
2023-06-12T14:06:01+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-at-conferences-during-january-2022/
2022-01-05T12:05:53+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-fda-clearance-of-investigational-new-drug-application-for-flt201-for-gaucher-disease-type-1/
2022-01-11T12:42:52+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1/
2022-01-07T09:49:03+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-2022-priorities/
2022-01-11T12:42:40+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-retirement-of-chief-financial-officer-and-succession-plan/
2022-01-11T12:42:29+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-announces-exclusive-license-with-the-national-cancer-institute-for-a-portfolio-of-t-cell-receptors-tcr-targeting-kras-and-tp53-mutations-for-the-treatment-of-cancer/
2022-01-11T13:10:03+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-provides-business-update-and-outlook-for-2022/
2022-01-13T13:21:08+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-announces-fda-investigational-new-drug-clearance-for-first-aav-based-gene-therapy-for-the-treatment-of-adrenomyeloneuropathy/
2022-01-25T12:34:20+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-on-its-fabry-and-gaucher-disease-aav-based-gene-therapies-at-the-18th-annual-worldsymposium/
2022-01-28T00:11:27+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-henning-r-stennicke-phd-as-chief-scientific-officer-to-lead-research-and-discovery/
2022-02-03T12:06:21+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2/
2022-02-03T21:05:33+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-strengthens-scientific-advisory-board-with-appointment-of-alena-gros-ph-d-and-ben-creelan-m-d/
2022-02-07T12:40:59+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-on-its-fabry-and-gaucher-disease-aav-based-gene-therapies-at-the-18th-annual-worldsymposiumtm/
2022-11-29T11:14:18+00:00
https://www.synconaltd.com/news-and-insights/news/third-quarter-update/
2022-02-10T07:02:11+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-strengthens-its-team-with-two-new-appointments/
2022-02-17T08:00:05+00:00
https://www.synconaltd.com/news-and-insights/news/fda-grants-fast-track-designation-to-sbt101-the-first-investigational-aav-based-gene-therapy-for-patients-with-adrenomyeloneuropathy-amn/
2022-02-17T12:55:41+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-completes-sale-of-gyroscope-to-novartis/
2022-03-04T09:48:32+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conference-call-on-march-10/
2022-02-21T12:05:59+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-to-present-at-upcoming-conferences/
2022-02-21T09:50:08+00:00
https://www.synconaltd.com/news-and-insights/news/omass-s-odyssion-drug-discovery-platform-makes-progress-in-drugging-the-undruggable-including-gasdermin-d/
2022-02-28T10:07:42+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-and-recent-business-highlights/
2023-06-12T14:05:57+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-describing-novel-cell-programming-technology/
2022-03-03T12:00:45+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3/
2023-06-12T14:05:57+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-to-present-new-preclinical-data-showcasing-aav-based-gene-therapy-candidate-for-adrenomyeloneuropathy-at-american-academy-of-neurology-annual-meeting/
2023-06-12T14:06:06+00:00
https://www.synconaltd.com/news-and-insights/news/omass-establishes-scientific-advisory-board-of-leading-experts-in-the-use-of-biophysical-approaches-to-drug-discovery/
2022-03-07T09:11:04+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference/
2022-03-08T13:08:07+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-to-present-first-clinical-data-from-the-phase-i-ii-study-of-anv419-at-the-aacr-annual-meeting-2022/
2022-03-09T08:56:07+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-first-patient-dosed-in-the-phase-1-2-b-lieve-dose-confirmation-trial-in-hemophilia-b/
2022-03-09T12:16:01+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-operational-progress/
2022-03-10T12:03:13+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-26-1-million-registered-direct-offering-of-american-depositary-shares/
2022-03-11T07:00:02+00:00
https://www.synconaltd.com/news-and-insights/news/fda-grants-orphan-drug-designation-to-sbt101-the-first-investigational-aav-based-gene-therapy-for-adrenomyeloneuropathy-amn/
2022-03-15T14:14:58+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-closes-26-1-million-registered-direct-offering-of-american-depositary-shares/
2022-03-15T21:13:47+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-participate-in-upcoming-investor-conferences/
2022-03-23T13:15:17+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-updated-development-plan-and-timelines-for-flt190-for-people-with-fabry-disease/
2022-03-24T11:05:12+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-participate-in-conferences-during-april-2022/
2022-03-29T12:03:43+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-receives-ema-orphan-medical-product-designation-for-obe-cel-for-treatment-of-acute-lymphoblastic-leukemia/
2022-03-31T12:05:18+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-full-year-2021-financial-results-and-business-highlights/
2022-04-01T07:00:34+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-host-kol-webcast-to-highlight-tracerx-study-presentations-from-the-2022-aacr-annual-meeting/
2022-04-04T13:11:41+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-and-pancella-inc-announce-a-research-evaluation-option-agreement-to-develop-ipsc-derived-macrophage-cell-therapy-for-inflammatory-organ-disease/
2022-04-05T07:10:14+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-announces-a-10m-extended-series-a-financing-from-syncona-ltd/
2022-04-05T07:10:14+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-at-upcoming-conferences/
2022-04-05T13:07:58+00:00
https://www.synconaltd.com/news-and-insights/news/updated-preclinical-data-support-potential-of-first-aav-based-gene-therapy-as-a-treatment-for-adrenomyeloneuropathy/
2022-04-05T13:12:47+00:00
https://www.synconaltd.com/news-and-insights/news/publication-in-nature-by-omass-founder-professor-dame-carol-robinson-shows-power-of-native-mass-spectrometry-in-drug-discovery-by-capturing-gpcr-signalling-in-native-membrane-environment/
2022-04-07T12:06:05+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-presents-compelling-data-from-the-phase-i-ii-study-of-anv419-during-the-aacr-annual-meeting-2022/
2022-11-29T11:13:35+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-announces-manufacturing-expansion-in-the-uk-and-partnership-for-manufacturing-in-the-us/
2022-04-12T13:02:52+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-appoints-paul-schneider-as-chief-financial-officer/
2022-04-19T13:03:40+00:00
https://www.synconaltd.com/news-and-insights/news/omass-ceo-ros-deegan-named-as-a-2022-in-vivo-rising-leader/
2022-04-19T12:14:53+00:00
https://www.synconaltd.com/news-and-insights/news/forcefield-therapeutics-launches-today-following-5-5m-commitment-from-syncona/
2023-06-12T14:05:57+00:00
https://www.synconaltd.com/news-and-insights/news/fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-to-autolus-car-t-cell-therapy-obe-cel-for-the-treatment-of-adult-b-all/
2022-04-25T12:05:30+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5/
2022-04-25T12:05:30+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-and-cellistic-enter-a-strategic-collaboration-to-develop-an-ipsc-derived-allogeneic-t-regulatory-treg-cell-therapy-platform/
2022-04-27T16:58:00+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-raises-100-million-in-series-b-financing-to-progress-drug-pipeline-in-immunology-and-rare-diseases/
2023-06-12T14:05:55+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-at-the-25th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy/
2022-05-02T22:34:27+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-three-novel-cell-programming-approaches-at-the-american-society-of-gene-cell-therapy-asgct-25th-annual-meeting-may-16-19-2022/
2022-05-02T22:33:29+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-to-present-at-upcoming-conferences/
2022-05-03T13:06:31+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-bernhard-ehmer-to-board-of-directors/
2022-05-04T13:02:48+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-first-quarter-2022-financial-results-and-operational-progress/
2022-05-05T12:05:14+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-doses-first-patient-with-higher-dose-cnet-in-phase-i-iia-chiron-trial-in-advanced-nsclc-and-initiates-enrollment-in-cohort-b-of-the-thetis-trial-cnet-pd-1-checkpoint-inhibitor-in-metastatic-malignant-melanoma/
2022-05-09T12:31:17+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-first-quarter-2022-financial-results-and-recent-business-highlights/
2022-05-10T12:54:10+00:00
https://www.synconaltd.com/news-and-insights/news/neogene-therapeutics-announces-approval-of-clinical-trial-application-for-its-first-phase-1-trial-of-novel-fully-individualized-tcr-therapy-to-treat-advanced-solid-tumors/
2022-05-10T13:03:43+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-first-quarter-2022-financial-results-and-business-highlights/
2022-05-11T07:00:00+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-four-clinical-data-updates-at-the-european-hematology-association-congress/
2022-05-12T16:04:13+00:00
https://www.synconaltd.com/news-and-insights/news/additional-preclinical-data-supports-clinical-advancement-of-first-aav-based-gene-therapy-for-adrenomyeloneuropathy/
2022-05-17T13:56:41+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-announces-56-million-series-b-financing-to-advance-novel-gene-therapies-for-neurological-conditions/
2022-05-18T11:11:34+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-participate-in-the-jefferies-healthcare-conference-being-held-in-new-york-from-june-8-10-2022/
2022-06-02T10:50:44+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement/
2022-06-06T07:03:00+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-fda-safe-to-proceed-letter-for-investigational-new-drug-ind-application-for-its-no-alpha-il-2-agonist-anv419/
2023-06-12T14:06:04+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-clinical-data-updates-at-the-european-hematology-association-congress/
2023-06-12T14:05:58+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-initiates-dosing-of-second-cohort-in-b-lieve-dose-confirmation-trial-of-flt180a-in-hemophilia-b/
2022-06-14T12:21:43+00:00
https://www.synconaltd.com/news-and-insights/news/cambridge-epigenetix-names-peter-fromen-as-chief-executive-officer/
2022-06-16T06:40:33+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-final-year-results-for-the-year-ended-31-march-2022/
2022-06-16T07:02:26+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-recognized-with-the-2022-ping-innovation-award/
2022-06-21T13:53:29+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-new-clinical-data-for-flt180a-in-hemophilia-b-at-international-society-on-thrombosis-and-haemostasis-congress/
2022-06-24T14:39:58+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-presents-design-of-innovative-natural-history-study-aimed-to-evolve-understanding-of-adrenomyeloneuropathy-and-inform-future-treatments/
2022-06-27T21:09:10+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-appoints-dr-amol-ketkar-as-chief-development-officer/
2022-06-30T13:08:44+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-appoints-james-taylor-as-chief-business-officer-and-cassian-yee-md-to-scientific-advisory-board/
2022-06-30T13:16:32+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-appoints-dr-gary-phillips-as-chief-business-officer/
2022-07-13T09:32:43+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-therapeutics-and-swanbio-therapeutics-announce-licensing-agreement-for-use-of-funsel-screening-platform/
2022-07-18T12:32:06+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-appoints-bill-symonds-to-its-board-of-directors/
2022-07-20T10:00:10+00:00
https://www.synconaltd.com/news-and-insights/news/new-england-journal-of-medicine-publishes-positive-long-term-data-on-freeline-s-gene-therapy-candidate-flt180a-for-people-with-hemophilia-b/
2023-06-12T14:05:52+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-second-quarter-2022-financial-results-on-august-4-2022/
2022-07-21T17:58:44+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-lead-horizon-europe-funded-consortium-to-advance-personalized-cell-therapy-manufacturing/
2022-07-21T13:13:12+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-therapeutics-expands-senior-team-with-key-appointments/
2022-07-26T12:49:18+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-to-present-new-data-from-the-phase-i-ii-study-of-anv419-at-the-esmo-congress-2022/
2022-07-29T10:41:14+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-second-quarter-2022-financial-results-and-operational-progress/
2022-08-04T12:07:34+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-second-quarter-2022-financial-results-and-business-highlights/
2022-08-09T12:03:40+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-second-quarter-2022-financial-results-and-recent-business-highlights/
2022-08-09T12:03:45+00:00
https://www.synconaltd.com/news-and-insights/news/first-quarter-update/
2022-08-16T07:12:43+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-therapeutics-report-of-foreign-issuer-rules-13a-16-and-15d-16-of-the-securities-exchange-act/
2022-08-30T07:00:38+00:00
https://www.synconaltd.com/news-and-insights/news/forcefield-therapeutics-researchers-identify-three-proteins-which-have-the-potential-to-prevent-heart-failure-after-heart-attack/
2022-08-31T19:05:53+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-to-present-updated-data-from-phase-i-ii-study-of-anv419-at-esmo/
2022-09-05T07:46:25+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-august-2022-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
2022-09-07T09:00:14+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-therapeutics-strengthens-scientific-leadership-with-the-appointment-of-alice-brown-as-chief-scientific-officer/
2022-09-07T15:27:13+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-presents-updated-data-from-the-phase-i-ii-study-of-anv419-during-the-esmo-congress-2022/
2022-11-29T11:04:54+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-collaboration-with-bristol-myers-squibb-for-use-of-autolus-proprietary-safety-switch-system/
2022-10-04T12:05:07+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-initiates-dosing-of-second-cohort-in-marvel-1-trial-of-flt190-gene-therapy-candidate-for-people-with-fabry-disease/
2022-10-04T12:05:07+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-september-2022-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
2022-10-05T21:05:33+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-co-founder-professor-charles-swanton-to-participate-in-expert-roundtable-highlighting-pivotal-nature-of-neoantigens-as-targets-in-cancer-cell-therapy/
2022-10-06T15:31:32+00:00
https://www.synconaltd.com/news-and-insights/news/moderna-exercises-option-to-license-proprietary-targeting-technology-from-autolus/
2022-10-12T12:05:59+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-third-quarter-2022-financial-results-on-november-3-2022/
2022-10-21T12:12:12+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-commences-tender-offer-for-all-outstanding-shares-of-applied-genetic-technologies-corporation/
2022-10-27T07:05:56+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-upcoming-poster-presentations-at-the-37th-society-for-immunotherapy-of-cancer-annual-meeting/
2022-10-31T13:08:40+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-third-quarter-2022-financial-results-and-operational-progress/
2022-11-03T11:13:54+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-three-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2022/
2022-11-29T11:04:20+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-and-ccrm-sign-collaboration-agreement-to-develop-and-scale-up-manufacturing-for-induced-pluripotent-stem-cell-ipsc-derived-macrophage-cell-therapies/
2022-11-07T09:49:40+00:00
https://www.synconaltd.com/news-and-insights/news/forcefield-therapeutics-presents-positive-preclinical-data-at-the-2022-scientific-sessions-of-american-heart-association/
2022-11-29T11:20:53+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-announces-the-appointment-of-lisa-bright-as-chair-of-its-board-of-directors/
2023-06-12T14:05:52+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-presents-updated-data-from-the-phase-i-ii-study-of-anv419-during-the-sitc-annual-meeting/
2022-11-29T11:04:03+00:00
https://www.synconaltd.com/news-and-insights/news/publication-in-nature-chemistry-demonstrates-the-benefits-of-native-mass-spectrometry-in-the-interrogation-of-target-ecosystems-and-drug-discovery/
2022-11-11T09:46:39+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-third-quarter-2022-financial-results-and-corporate-update/
2022-12-01T09:33:23+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-half-year-results-for-the-period-ending-30-september-2022/
2022-11-17T07:05:18+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-chief-executive-officer-richard-francis-appointed-chief-executive-officer-of-teva-pharmaceutical-industries-ltd/
2022-11-28T17:46:46+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-receives-approval-to-transfer-to-nasdaq-capital-market/
2022-11-30T07:54:34+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-appoints-dr-eduard-gasal-as-chief-medical-officer/
2023-06-12T14:05:50+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-handover-of-first-clean-rooms-of-new-stevenage-uk-manufacturing-facility/
2022-11-30T12:33:09+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-early-proof-of-concept-of-safety-and-clinical-activity-of-clonal-neoantigen-reactive-t-cells-at-the-esmo-immuno-oncology-annual-congress-2022/
2022-12-01T07:47:00+00:00
https://www.synconaltd.com/news-and-insights/news/positive-initial-clinical-data-from-the-b-lieve-dose-confirmation-trial-for-flt180a-in-hemophilia-b-presented-at-the-international-society-on-thrombosis-and-haemostasis-congress/
2022-12-01T09:48:38+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-presents-encouraging-phase-i-iia-update-on-clonal-neoantigen-reactive-t-cells-in-advanced-nsclc-and-melanoma-at-esmo-io-congress-2022/
2022-12-06T11:05:36+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-pivotal-phase-2-felix-clinical-trial-has-met-primary-endpoint-at-interim-analysis/
2022-12-09T06:33:58+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-receive-70-million-in-milestone-payments-from-blackstone-life-sciences/
2022-12-09T06:34:08+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-pricing-of-public-offering/
2022-12-09T06:35:36+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2022/
2022-12-12T15:05:32+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-initiates-first-in-human-study-of-aav-gene-therapy-for-adrenomyeloneuropathy/
2022-12-15T13:05:56+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/
2022-12-20T13:44:48+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-partial-exercise-of-underwriters-option-to-purchase-additional-adss/
2022-12-21T21:26:57+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-collaboration-with-cabaletta-bio-for-use-of-autolus-safety-switch-system-in-cell-therapies-for-autoimmune-disease/
2023-01-09T12:10:51+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-publishes-preclinical-proof-of-concept-data-for-flt190-its-aav-gene-therapy-candidate-for-fabry-disease-in-the-nature-journal-gene-therapy/
2023-01-19T13:10:05+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-board-changes/
2023-01-20T12:09:24+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-doses-first-patient-in-a-phase-i-ii-study-of-anv419-as-monotherapy-or-in-combination-with-check-point-inhibitors-in-patients-with-advanced-melanoma/
2023-02-02T08:45:28+00:00
https://www.synconaltd.com/news-and-insights/news/third-quarter-update-fy2022-3/
2023-02-07T07:00:25+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-closing-of-sale-of-its-cmc-focused-german-subsidiary/
2023-02-10T12:28:30+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-full-year-2022-financial-results-and-operational-progress/
2023-03-07T12:05:05+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-reports-q3-2022-financial-results-and-business-highlights/
2023-03-07T12:07:53+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-has-no-business-relationship-with-silicon-valley-bank/
2023-03-13T11:05:31+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-resignation-of-chief-financial-officer/
2023-03-14T11:27:49+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-first-patient-dosed-with-anv419-in-a-phase-i-ii-study-of-anv419-in-patients-with-multiple-myeloma/
2023-03-16T10:25:42+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-presentation-of-a-novel-development-compound-at-the-2023-american-association-for-cancer-research-annual-meeting/
2023-03-23T09:41:09+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-expands-its-cmc-capabilities-with-key-hires/
2023-03-30T10:10:20+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-in-molecular-therapy/
2023-04-04T12:35:51+00:00
https://www.synconaltd.com/news-and-insights/news/mosaic-therapeutics-closes-28m-series-a-funding-and-appoints-brian-gladsden-as-ceo/
2023-05-02T15:28:43+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-appoints-roel-bulthuis-as-managing-partner/
2023-04-05T10:06:38+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-announces-new-phase-of-growth-with-move-to-new-facilities-and-team-expansion-to-support-portfolio-progress/
2023-04-19T09:00:05+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-host-virtual-capital-markets-day/
2023-04-25T12:04:02+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-announces-grant-of-us-patent-covering-the-treatment-of-patients-with-an-immunotherapy-targeting-neoantigens-based-on-tumor-hla-status/
2023-04-25T12:09:45+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-data-from-auto1-22-trial-in-pediatric-acute-lymphoblastic-leukemia-in-an-oral-presentation-at-the-ebmt-49th-annual-meeting/
2023-04-27T09:09:35+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-in-molecular-therapy-nucleic-acids/
2023-05-02T16:20:36+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-selects-cardinal-health-as-u-s-commercial-distribution-partner/
2023-04-27T12:20:48+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-asco/
2023-04-27T12:22:14+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-appoints-liver-disease-expert-dr-clifford-a-brass-as-chief-medical-officer/
2023-05-02T09:18:22+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-first-quarter-2023-financial-results-and-operational-progress/
2023-05-04T12:17:51+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-new-immunogenicity-prediction-application-of-its-ai-powered-peleus-platform-uniquely-identifies-the-most-potent-t-cell-antigens/
2023-06-12T14:05:53+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-therapeutics-confirms-substantial-burden-of-disease-of-adrenomyeloneuropathy-amn-in-both-men-and-women/
2023-05-10T12:24:13+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-first-quarter-2023-financial-results-and-recent-business-highlights/
2023-05-10T12:24:09+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-completes-ads-ratio-change/
2023-05-12T14:13:05+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha/
2023-05-12T12:07:21+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-announces-appointment-of-new-board-chair-and-series-b-extension/
2023-05-15T08:04:04+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-positive-results-from-pivotal-phase-2-felix-study-in-adult-r-r-b-all-at-asco/
2023-06-13T08:09:19+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-at-2023-jefferies-healthcare-conference/
2023-06-02T15:05:46+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-hold-analyst-call-to-highlight-data-at-asco-from-the-pivotal-phase-2-felix-study-of-obe-cel-data-in-adult-r-r-b-all/
2023-06-03T11:53:14+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-first-quarter-2023-financial-results-and-business-highlights/
2023-06-03T11:46:21+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-granted-ilap-designation-in-united-kingdom-by-mhra-for-flt201-an-investigational-gene-therapy-for-the-treatment-of-gaucher-disease/
2023-06-03T11:51:14+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-to-hold-annual-general-meeting-agm-of-shareholders-on-friday-june-30-2023/
2023-06-06T11:17:42+00:00
https://www.synconaltd.com/news-and-insights/news/beacon-therapeutics-launches-with-96-million-120-million-to-develop-a-new-generation-of-gene-therapies-for-retinal-diseases-resulting-in-blindness/
2023-06-12T15:31:54+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-at-upcoming-conferences-2023/
2023-06-13T16:31:12+00:00
https://www.synconaltd.com/news-and-insights/news/quell-therapeutics-signs-a-collaboration-exclusive-option-and-license-agreement-with-astrazeneca-to-develop-manufacture-and-commercialize-engineered-treg-cell-therapies-for-autoimmune-diseases/
2023-06-13T17:45:22+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-full-year-results-for-the-12-months-ended-31-march-2023/
2023-06-15T06:05:55+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-positive-results-from-auto4-in-relapsed-refractory-trbc1-positive-peripheral-t-cell-lymphoma/
2023-06-16T11:22:19+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-strengthens-its-board-with-the-appointment-of-dr-robert-iannone-as-a-non-executive-director/
2023-06-20T11:18:23+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-strengthens-its-team-with-senior-appointments/
2023-06-26T07:45:58+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-first-patient-dosed-with-its-novel-gene-therapy-candidate-for-gaucher-disease-and-unveils-research-program-in-gba1-linked-parkinson-s-disease/
2023-06-26T11:59:30+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-in-cancer-immunology-research/
2023-07-06T11:42:08+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-a-publication-in-nature-medicine-on-obe-cel-in-pediatric-acute-lymphoblastic-leukemia/
2023-07-06T11:15:12+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-strengthens-its-executive-team-with-the-appointment-of-simon-ramsden-as-chief-financial-officer/
2023-07-10T07:40:18+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-second-quarter-2023-financial-results-and-host-conference-call-on-august-3-2023/
2023-07-19T11:30:25+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-appointment-of-robert-f-dolski-as-chief-financial-officer/
2023-07-19T13:49:56+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-expands-leadership-team-with-two-new-appointments/
2023-08-02T08:12:03+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-therapeutics-appoints-sachin-kelkar-as-cfo-following-appointment-of-julian-hanak-as-ceo/
2023-08-02T09:22:20+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-second-quarter-2023-financial-results-and-operational-progress/
2023-08-04T11:30:17+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-highlights/
2023-08-04T11:36:27+00:00
https://www.synconaltd.com/news-and-insights/news/fy2023-4-first-quarter-update/
2023-08-10T06:20:42+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-appoints-dr-amir-hefni-as-chief-executive-officer/
2023-08-14T08:33:28+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-reports-second-quarter-2023-financial-results-and-business-highlights/
2023-08-15T11:12:21+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-data-from-auto1-22-trial-in-pediatric-acute-lymphoblastic-leukemia-published-in-the-journal-blood/
2023-10-25T16:00:54+00:00
https://www.synconaltd.com/news-and-insights/news/purespring-appoints-fredrik-erlandsson-as-chief-medical-officer-and-peter-mulcahy-as-chief-people-officer/
2023-09-06T13:53:33+00:00
https://www.synconaltd.com/news-and-insights/news/update-on-gyroscope-and-associated-milestone-payments/
2023-09-11T08:16:06+00:00
https://www.synconaltd.com/news-and-insights/news/forcefield-therapeutics-appoints-john-tsai-md-as-chief-executive-officer/
2023-09-27T08:35:20+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-adds-mark-namchuk-phd-to-scientific-advisory-board/
2023-09-27T08:47:13+00:00
https://www.synconaltd.com/news-and-insights/news/launch-of-share-buyback-programme/
2023-09-29T08:06:21+00:00
https://www.synconaltd.com/news-and-insights/news/share-buyback-programme/
2023-09-29T08:08:14+00:00
https://www.synconaltd.com/news-and-insights/news/clade-therapeutics-announces-the-acquisition-of-gadeta-b-v/
2023-10-02T14:20:12+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-announces-positive-initial-clinical-data/
2023-10-25T13:42:01+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-advances-to-higher-dose-cohort-in-first-in-human-study-of-gene-therapy-for-adrenomyeloneuropathy/
2023-10-04T13:03:15+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-third-quarter-2023-financial-results-and-host-conference-call-on-november-2-2023/
2023-10-11T11:59:49+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-poster-presentation-at-the-2023-european-society-for-medical-oncology-annual-meeting/
2023-10-25T13:41:30+00:00
https://www.synconaltd.com/news-and-insights/news/swanbio-evolves-leadership-team-with-appointment-of-executive-chair-and-chief-operating-officer/
2023-10-16T10:35:25+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-to-present-new-clinical-data-for-flt201-in-gaucher-disease-in-oral-presentation-at-upcoming-esgct-30th-annual-congress/
2023-10-16T11:05:26+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-host-virtual-event-to-discuss-the-company-s-obe-cel-program-in-systemic-lupus-erythematosus/
2023-10-17T11:48:05+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-presents-positive-new-data-from-phase-1-2-galileo-1-trial-of-flt201-its-novel-gene-therapy-candidate-in-gaucher-disease-at-esgct-30th-annual-congress/
2023-10-25T13:40:12+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-presentation-of-anv600-preclinical-data-supporting-combination-therapy-with-therapeutic-pd-1-inhibitors/
2023-11-01T09:53:06+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-participation-in-upcoming-conferences/
2023-11-06T14:43:26+00:00
https://www.synconaltd.com/news-and-insights/news/resolution-therapeutics-founders-present-clinical-proof-of-concept-for-macrophage-cell-therapy-in-end-stage-liver-disease-at-aasld/
2023-11-13T09:34:03+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-reports-third-quarter-2023-financial-results-and-recent-highlights/
2023-11-14T09:55:22+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-third-quarter-2023-financial-results-and-business-updates/
2023-11-14T09:53:15+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-host-analyst-investor-event-at-the-american-society-of-hematology-ash-annual-meeting-2023/
2023-11-15T12:08:28+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-half-year-results-for-the-period-ending-30-september-2023/
2023-11-16T07:00:10+00:00
https://www.synconaltd.com/news-and-insights/news/omass-therapeutics-expands-leadership-team-with-the-appointment-of-melissa-faris-as-chief-business-officer/
2023-11-16T08:04:23+00:00
https://www.synconaltd.com/news-and-insights/news/syncona-to-acquire-freeline-therapeutics/
2023-11-22T12:36:23+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-submits-biologics-license-application-to-u-s-food-and-drug-administration-for-obecabtagene-autoleucel-obe-cel-for-patients-with-relapsed-refractory-r-r-adult-b-cell-acute-lymphoblastic-leukemia-all/
2023-11-27T12:06:21+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-presents-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2023/
2023-12-11T10:43:03+00:00
https://www.synconaltd.com/news-and-insights/news/anaveon-announces-publication-of-anv419-phase-i-data-in-the-journal-for-immunotherapy-of-cancer/
2023-12-14T09:00:43+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-announces-publication-of-nature-cancer-comment-on-strategy-for-improved-neoantigen-immunogenicity-prediction/
2023-12-18T12:54:01+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-changes-to-its-board-of-directors/
2023-12-22T12:05:41+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-the-appointment-of-robert-w-azelby-to-its-board-of-directors/
2024-01-10T12:24:54+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-in-acs-chemical-biology/
2024-01-23T12:16:57+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-acceptance-of-biologics-license-application-for-obecabtagene-autoleucel-obe-cel-as-a-potential-treatment-for-relapsed-refractory-adult-b-cell-acute-lymphoblastic-leukemia-all/
2024-02-01T09:55:42+00:00
https://www.synconaltd.com/news-and-insights/news/beacon-announces-unmasked-three-month-data-from-phase-2-skyline-trial-of-agtc-501-for-x-linked-retinitis-pigmentosa/
2024-02-01T10:13:42+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-submits-biologics-license-application-to-u-s-food-and-drug-administration-for-obecabtagene-autoleucel-obe-cel-for-patients-with-relapsed-refractory-r-r-adult-b-cell-acute-lymphoblastic-leukemia-all-1/
2024-02-01T10:01:37+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-present-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2023-in-two-oral-presentations-and-two-poster-presentations/
2024-02-01T10:06:34+00:00
https://www.synconaltd.com/news-and-insights/news/achilles-therapeutics-to-present-at-the-10th-annual-immuno-oncology-360-conference/
2024-02-05T12:09:52+00:00
https://www.synconaltd.com/news-and-insights/news/fy2023-4-third-quarter-update/
2024-02-08T07:14:59+00:00
https://www.synconaltd.com/news-and-insights/news/biontech-and-autolus-announce-strategic-car-t-cell-therapy-collaboration-to-advance-pipeline-and-expand-late-stage-programs/
2024-02-08T11:35:29+00:00
https://www.synconaltd.com/news-and-insights/news/beacon-therapeutics-announces-positive-12-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa/
2024-02-08T13:26:00+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-announces-pricing-of-underwritten-offering/
2024-02-08T12:21:58+00:00
https://www.synconaltd.com/news-and-insights/news/freeline-shareholders-approve-acquisition-by-syncona/
2024-02-12T17:08:26+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-in-nature-communications/
2024-02-22T12:10:25+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-to-report-full-year-2023-financial-results-and-business-updates-on-march-14-2024/
2024-02-29T12:04:54+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-publication-in-blood-cancer-journal/
2024-03-11T11:18:45+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-receives-medicines-and-healthcare-products-regulatory-agency-mhra-certification-for-nucleus-commercial-manufacturing-site/
2024-03-12T11:15:44+00:00
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-reports-full-year-2023-financial-results-and-business-updates/
2024-03-14T11:05:41+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/
2023-06-12T14:28:42+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/quell-therapeutics-and-an-emerging-area-of-cell-therapy/
2021-06-07T12:48:48+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/found-build-and-fund/
2021-06-07T12:49:04+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/founding-quell-therapeutics/
2021-06-07T13:21:04+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/building-syncona-s-gene-therapy-platform/
2021-06-07T12:46:21+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/an-introduction-to-gene-therapy/
2021-06-07T12:49:18+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/introduction-to-richard-francis-chief-executive-of-purespring-therapeutics/
2021-06-08T09:35:05+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/introduction-from-quell-therapeutics-ceo-iain-mcgill/
2021-06-08T09:52:04+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/quell-the-science-and-the-unmet-medical-need-for-patients/
2021-06-08T09:49:27+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/introducing-resolution-therapeutics/
2021-06-08T10:28:03+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/introduction-to-purespring/
2023-06-12T14:05:53+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/syncona-fy20-martin-murphy-discusses-fy20-results/
2021-06-08T10:35:08+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/syncona-fy20-martin-murphy-discusses-the-impact-of-covid-19/
2021-06-08T10:49:57+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/syncona-fy20-martin-murphy-discusses-the-outlook-for-syncona/
2021-06-08T10:52:46+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/achilles-doses-first-patient/
2021-06-07T13:20:33+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/gene-therapy-explained/
2021-06-07T12:47:18+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/syncona-s-martin-murphy-and-freddie-dear-quell-series-a-expansion/
2021-06-08T10:01:16+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/delivering-transformational-treatments-for-patients/
2021-06-07T12:47:07+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/nightstar-testimonials/
2021-06-07T12:47:38+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/measuring-the-potential-impact-of-a-gene-therapy-for-patients/
2021-06-07T12:47:54+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/achilles-therapeutics-and-the-advent-of-immunotherapy/
2021-06-07T13:21:32+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/marie-curie-case-study/
2021-06-02T17:16:40+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/uniting-against-dementia-with-alzheimer-s-society/
2021-06-17T07:35:33+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/partnering-with-our-charities/
2021-06-17T07:35:27+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/anaveon-doses-first-patient/
2021-06-24T07:01:47+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/encouraging-diversity-in-the-next-generation-of-scientists/
2021-06-29T09:13:04+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/ed-hodgkin-provides-his-perspectives-from-a-career-in-early-stage-biotech/
2021-09-17T09:21:53+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/alex-hamilton-on-manufacturing-in-cell-and-gene-therapy-and-the-role-of-development-partnerships/
2023-06-12T14:05:58+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/syncona-ceo-martin-murphy-discusses-clade-series-a-financing/
2021-11-03T11:13:11+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/ed-hodgkin-and-magdalena-jonikas-discuss-omass-series-b/
2022-04-28T10:23:41+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/welcoming-our-first-windsor-fellowship-intern-to-syncona/
2022-08-11T16:15:46+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/building-a-global-leader-in-retinal-gene-therapy/
2023-07-19T11:31:18+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/scaling-for-growth/
2023-06-12T14:28:44+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/good-science-must-survive-in-challenging-markets/
2023-06-12T14:28:43+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/leveraging-the-syncona-team-for-our-next-phase-of-growth/
2023-06-12T14:28:44+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/launching-beacon-therapeutics/
2023-06-12T15:43:37+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/taking-a-proactive-approach-to-portfolio-company-sustainability/
2023-07-20T08:20:33+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/modality-precision-is-the-new-precision-in-medicine/
2023-08-08T12:52:57+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/expansion-of-our-senior-team/
2024-01-16T11:03:08+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/building-a-platform-for-the-next-generation-of-investors/
2024-01-25T09:05:51+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/navigating-the-biotech-landscape-a-journey-from-big-pharma-to-innovative-startups/
2024-02-15T14:02:17+00:00
https://www.synconaltd.com/news-and-insights/insights-articles/challenges-continue-but-brighter-days-on-the-horizon/
2024-02-26T21:25:52+00:00
https://www.synconaltd.com/news-and-insights/publications-presentations/
2023-06-12T14:28:42+00:00
https://www.synconaltd.com/news-and-insights/newsletters/
2023-09-06T10:13:06+00:00
https://www.synconaltd.com/investors/
2024-02-08T07:18:34+00:00
https://www.synconaltd.com/investors/kpis/
2023-06-28T10:55:27+00:00
https://www.synconaltd.com/investors/results-and-presentations/
2023-07-03T09:54:31+00:00
https://www.synconaltd.com/investors/rns-and-inside-information/
2023-06-13T13:28:38+00:00
https://www.synconaltd.com/investors/share-price-centre/
2023-06-13T14:06:28+00:00
https://www.synconaltd.com/investors/governance/
2023-09-29T15:02:53+00:00
https://www.synconaltd.com/investors/governance/our-committees/
2023-11-21T12:17:24+00:00
https://www.synconaltd.com/investors/governance/how-we-communicate-with-our-stakeholders/
2023-06-28T07:21:58+00:00
https://www.synconaltd.com/investors/regulatory-publications/
2023-06-12T14:30:25+00:00
https://www.synconaltd.com/investors/financial-calendar/
2024-01-04T13:57:24+00:00
https://www.synconaltd.com/investors/analysts-and-advisers/
2023-06-12T14:30:27+00:00
https://www.synconaltd.com/investors/shareholder-information/
2024-02-07T17:37:47+00:00
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/
2023-06-12T14:30:28+00:00
https://www.synconaltd.com/investors/faqs/
2024-03-11T12:05:55+00:00
https://www.synconaltd.com/contact/
2023-06-12T14:50:35+00:00
https://www.synconaltd.com/accessibility/
2023-09-07T10:52:44+00:00
https://www.synconaltd.com/privacy-cookies/
2023-06-12T14:12:01+00:00
https://www.synconaltd.com/employee-privacy-notice/
2023-06-12T14:11:46+00:00
https://www.synconaltd.com/third-party-privacy-notice/
2023-06-12T14:11:35+00:00
https://www.synconaltd.com/email-alerts/
2024-01-08T19:23:30+00:00